Gastroparesis  >>  velusetrag (TD-5108)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
velusetrag (TD-5108) / Innoviva
NCT01718938: Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Completed
2
34
US
velusetrag dose 1, TD-5108, velusetrag dose 2, velusetrag dose 3, placebo
Theravance Biopharma, Alfasigma S.p.A.
Gastroparesis
12/13
02/14
DIGEST, NCT02267525 / 2014-003250-13: The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability () Study

Completed
2
233
NA
Velusetrag, TD-5108, Placebo
Theravance Biopharma, Alfasigma S.p.A.
Gastroparesis
06/17
06/17

Download Options